These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
239 related articles for article (PubMed ID: 32714578)
1. Targeting bone morphogenetic protein signalling in midbrain dopaminergic neurons as a therapeutic approach in Parkinson's disease. O'Keeffe GW; Hegarty SV; Sullivan AM Neuronal Signal; 2017 Apr; 1(2):NS20170027. PubMed ID: 32714578 [TBL] [Abstract][Full Text] [Related]
2. The potential of bone morphogenetic protein 2 as a neurotrophic factor for Parkinson's disease. Goulding SR; Sullivan AM; O'Keeffe GW; Collins LM Neural Regen Res; 2020 Aug; 15(8):1432-1436. PubMed ID: 31997802 [TBL] [Abstract][Full Text] [Related]
3. Quinacrine and Niclosamide Promote Neurite Growth in Midbrain Dopaminergic Neurons Through the Canonical BMP-Smad Pathway and Protect Against Neurotoxin and α-Synuclein-Induced Neurodegeneration. Goulding SR; Lévesque M; Sullivan AM; Collins LM; O'Keeffe GW Mol Neurobiol; 2021 Jul; 58(7):3405-3416. PubMed ID: 33713017 [TBL] [Abstract][Full Text] [Related]
4. BMP2 and GDF5 induce neuronal differentiation through a Smad dependant pathway in a model of human midbrain dopaminergic neurons. Hegarty SV; Sullivan AM; O'Keeffe GW Mol Cell Neurosci; 2013 Sep; 56():263-71. PubMed ID: 23831389 [TBL] [Abstract][Full Text] [Related]
8. BMP-Smad 1/5/8 signalling in the development of the nervous system. Hegarty SV; O'Keeffe GW; Sullivan AM Prog Neurobiol; 2013 Oct; 109():28-41. PubMed ID: 23891815 [TBL] [Abstract][Full Text] [Related]
9. Bone morphogenetic proteins: neurotrophic roles for midbrain dopaminergic neurons and implications of astroglial cells. Jordan J; Böttner M; Schluesener HJ; Unsicker K; Krieglstein K Eur J Neurosci; 1997 Aug; 9(8):1699-709. PubMed ID: 9283824 [TBL] [Abstract][Full Text] [Related]
11. Gene co-expression analysis of the human substantia nigra identifies BMP2 as a neurotrophic factor that can promote neurite growth in cells overexpressing wild-type or A53T α-synuclein. Goulding SR; Sullivan AM; O'Keeffe GW; Collins LM Parkinsonism Relat Disord; 2019 Jul; 64():194-201. PubMed ID: 31000327 [TBL] [Abstract][Full Text] [Related]
12. GDNF fails to exert neuroprotection in a rat α-synuclein model of Parkinson's disease. Decressac M; Ulusoy A; Mattsson B; Georgievska B; Romero-Ramos M; Kirik D; Björklund A Brain; 2011 Aug; 134(Pt 8):2302-11. PubMed ID: 21712347 [TBL] [Abstract][Full Text] [Related]
13. Neurotrophic factors: from neurodevelopmental regulators to novel therapies for Parkinson's disease. Hegarty SV; O'Keeffe GW; Sullivan AM Neural Regen Res; 2014 Oct; 9(19):1708-11. PubMed ID: 25422631 [TBL] [Abstract][Full Text] [Related]
14. Differential effects of growth/differentiation factor 5 and glial cell line-derived neurotrophic factor on dopaminergic neurons and astroglia in cultures of embryonic rat midbrain. Wood TK; McDermott KW; Sullivan AM J Neurosci Res; 2005 Jun; 80(6):759-66. PubMed ID: 15880784 [TBL] [Abstract][Full Text] [Related]
15. Gene Co-expression Analysis Identifies Histone Deacetylase 5 and 9 Expression in Midbrain Dopamine Neurons and as Regulators of Neurite Growth via Bone Morphogenetic Protein Signaling. Mazzocchi M; Wyatt SL; Mercatelli D; Morari M; Morales-Prieto N; Collins LM; Sullivan AM; O'Keeffe GW Front Cell Dev Biol; 2019; 7():191. PubMed ID: 31572723 [TBL] [Abstract][Full Text] [Related]
16. GDNF family ligands: a potential future for Parkinson's disease therapy. Mickiewicz AL; Kordower JH CNS Neurol Disord Drug Targets; 2011 Sep; 10(6):703-11. PubMed ID: 21838676 [TBL] [Abstract][Full Text] [Related]
17. Bone morphogenetic proteins. Chen D; Zhao M; Mundy GR Growth Factors; 2004 Dec; 22(4):233-41. PubMed ID: 15621726 [TBL] [Abstract][Full Text] [Related]
18. Evidence for dopaminergic axonal degeneration as an early pathological process in Parkinson's disease. O'Keeffe GW; Sullivan AM Parkinsonism Relat Disord; 2018 Nov; 56():9-15. PubMed ID: 29934196 [TBL] [Abstract][Full Text] [Related]
19. 6-Hydroxydopamine induces distinct alterations in GDF5 and GDNF mRNA expression in the rat nigrostriatal system in vivo. Gavin AM; Walsh S; Wyatt S; O'Keeffe GW; Sullivan AM Neurosci Lett; 2014 Feb; 561():176-81. PubMed ID: 24373993 [TBL] [Abstract][Full Text] [Related]
20. The noradrenergic system is necessary for survival of vulnerable midbrain dopaminergic neurons: implications for development and Parkinson's disease. Hassani OK; Rymar VV; Nguyen KQ; Huo L; Cloutier JF; Miller FD; Sadikot AF Neurobiol Aging; 2020 Jan; 85():22-37. PubMed ID: 31734438 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]